Peptide Profile

Thymosin Beta-4

Tissue Repair Peptide (TB-500)

Research Only10 sourcesShop Thymosin Beta-4

Overview

Composition

Naturally occurring 43-amino-acid peptide first isolated from thymus gland tissue, present in high concentrations in blood platelets, wound fluid, and most tissues; often used as synthetic fragment TB-500 (containing the active sequence)

Mechanism of Action

Binds to actin (key cytoskeletal protein) to regulate cell migration, proliferation, and differentiation; promotes angiogenesis (new blood vessel formation), reduces inflammation, modulates immune responses, and supports tissue remodeling and repair

Primary Effects

Studied in injury models for wound healing, inflammation and fibrosis modulation, angiogenesis, musculoskeletal recovery, neuroprotection, and cardioprotection

Discovery & Background

First isolated from thymus gland in the 1960s-1970s during research on thymic peptides and immune function; later recognized for widespread tissue repair and regenerative properties beyond immune modulation

1960s-1970s: Discovery and characterization. 1980s-1990s: Expansion into wound healing and angiogenesis research. 2000s-present: Exploration in sports medicine, cardiac repair, neuroprotection, and regenerative medicine; synthetic TB-500 fragment widely used

Not FDA-approved for therapeutic use in humans; remains investigational/research compound. Veterinary use (e.g., equine medicine for tendon/ligament injuries) has some approval/acceptance internationally

Research Overview

Extensive preclinical research demonstrates thymosin beta-4's tissue repair, anti-inflammatory, and regenerative properties across multiple organ systems

01
Accelerates wound closure and tissue regeneration in animal models (skin, muscle, tendon, corneal injuries)
02
Promotes angiogenesis and neovascularization in ischemic tissues
03
Reduces inflammation and fibrosis, improving healing quality (less scarring)
04
Cardioprotection: improves outcomes in myocardial infarction (heart attack) models by reducing scar size, enhancing cardiac function, and promoting vessel formation
05
Neuroprotection: supports neuronal survival, reduces brain injury in stroke and TBI models
06
Enhances stem cell recruitment and differentiation to injury sites
07
Improves flexibility, range of motion, and functional recovery in musculoskeletal injuries
08
Well-tolerated in animal studies with minimal adverse effects
09
Small human trials and case series exist in wound-healing and cardiac-repair contexts, but large-scale RCTs are lacking
10
Sports-medicine and regenerative-wellness use is largely off-label or uncontrolled

No FDA approval for human use; lacks large-scale RCTs. Evidence from preclinical models, veterinary use, and small human exploratory studies

Safety Considerations

Monitoring

Wound/injury healing progress (visual assessment, imaging)
Pain and inflammation levels
Range of motion and functional capacity
Cardiac function markers (if using for cardioprotection)
Evidence quality by indication and study type

Side Effects

Generally Well-Tolerated

Human adverse-event reporting remains limited and heterogeneous
Rare reports of fatigue or lethargy (usually mild)
Minimal systemic side effects in preclinical and anecdotal human use

Theoretical Concerns

Potential for promoting angiogenesis in tumors (theoretical—avoid in active cancer)
Long-term effects on fibrosis, vessel growth, and tumor biology remain uncertain

Contraindications

Active cancer or history of malignancy (angiogenesis concerns)
Hypersensitivity to thymosin beta-4/TB-500 or components
Pregnancy or breastfeeding (insufficient safety data)
Caution in conditions where angiogenesis may be undesirable (e.g., proliferative retinopathy)

Educational Notice

Thymosin beta-4/TB-500 has substantial preclinical literature for wound healing, tissue repair, cardioprotection, and neuroprotection, but it is not FDA-approved for human therapeutic use. Human clinical data remain limited to small trials, case series, and uncontrolled reports. Long-term safety and efficacy require further study, angiogenesis-related cancer caution remains relevant, and compounded quality varies.

References